Mayo Clinic has joined forces with molecular diagnostics provider Naveris to begin the DART 2.0 prospective clinical study to assess the latter’s blood test, NavDx.

The trial will assess the potential of NavDx, a blood test for tumour tissue-modified viral-human papillomavirus DNA, to enhance treatment selection in patients with HPV-driven head and neck cancer.

NavDx analyses tumour-derived viral DNA in patients’ blood samples to provide non-invasively tracking of molecular residual disease and recurrence.

Naveris chief medical officer Barry Berger said: “This trial will build upon the validation of NavDx as a valuable tool for assessing the risk of post-treatment cancer recurrence in these patients, enabling earlier detection of recurrence and application of therapeutic interventions.”

Data from an earlier phase III MC1675 DART clinical study showed a molecular residual disease, which was detected by NavDx, is a major risk factor for cancer relapse in head and neck cancer patients.

NavDx will allow physicians to select the treatment options suitable for each individual patient, thereby enhancing patient outcomes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Naveris founder and CEO Piyush Gupta said: “This clinical trial represents a significant step forward in personalised medicine for head and neck cancer patients.

“NavDx has the potential to be a game-changer in treatment selection, allowing physicians to tailor treatment plans to individual patients based on their unique biomarker profiles.”

In September last year, Naveris raised $33.4m in Series A financing, bringing its total investment to $51m to boost the commercialisation of the NavDx blood test.